Cargando…

Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate

BACKGROUND: Radiotherapy (RT) alone or in combination with androgen deprivation therapy (ADT) is most common non-operative treatments for localised prostate cancer (PC). Some circulatory cytokines are believed to play an important role in RT resistance and lead to tumour progression, invasion, and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Jagtar, Sohal, Sukhwinder Singh, Ahuja, Kiran, Lim, Aijye, Duncan, Henry, Thachil, Thanuja, De Ieso, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290633/
https://www.ncbi.nlm.nih.gov/pubmed/32566573
http://dx.doi.org/10.21037/atm-19-1913
_version_ 1783545723264958464
author Singh, Jagtar
Sohal, Sukhwinder Singh
Ahuja, Kiran
Lim, Aijye
Duncan, Henry
Thachil, Thanuja
De Ieso, Paolo
author_facet Singh, Jagtar
Sohal, Sukhwinder Singh
Ahuja, Kiran
Lim, Aijye
Duncan, Henry
Thachil, Thanuja
De Ieso, Paolo
author_sort Singh, Jagtar
collection PubMed
description BACKGROUND: Radiotherapy (RT) alone or in combination with androgen deprivation therapy (ADT) is most common non-operative treatments for localised prostate cancer (PC). Some circulatory cytokines are believed to play an important role in RT resistance and lead to tumour progression, invasion, and angiogenesis. The aim of this study is to assess the influence of ADT and RT on the expression of circulatory cytokines levels in plasma at different time points. METHODS: Between Nov 2015 and Aug 2016, 18 patients with localized PC were selected for this clinical study. All patients had received neoadjuvant ADT using a leuteinizing hormone-releasing hormone (LH-RH) analogs prior to RT. Peripheral blood samples were collected prior to ADT, before RT, at the end of RT and 3 months after the completion of RT. Blood plasma samples were monitored for the pro-inflammatory and profibrotic cytokines TNF-α, TGF-β1, IL-6, and IL-8, using enzyme-linked immunosorbent assay (ELISA) procedures. RESULTS: The concentration of TGF-β1 rose while IL-6 levels declined in post-ADT samples when compared pre-ADT. Levels of TGF-β1 increased in post-RT blood plasma compared to pre-RT blood plasma. Those changes were not statically significant. Three months post-RT completion, TGF-β1 levels decreased and IL-6 and IL-8 levels increased. Although levels of TGF-β1, IL-6 and IL-8 were found to be altered 3 months post-RT completion, only changes in IL-8 levels were found to be statistically significant (P=0.05). CONCLUSIONS: In conclusion the changes in cytokines levels have been found after ADT and RT, which strengthen the finding of other clinical studies. Accept that small numbers of samples made difficult to attain significant results. Large clinical studies will be required to validate these findings and hopefully become useful biomarkers in the clinical setting to predict patient outcome and success of treatment received.
format Online
Article
Text
id pubmed-7290633
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-72906332020-06-19 Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate Singh, Jagtar Sohal, Sukhwinder Singh Ahuja, Kiran Lim, Aijye Duncan, Henry Thachil, Thanuja De Ieso, Paolo Ann Transl Med Original Article BACKGROUND: Radiotherapy (RT) alone or in combination with androgen deprivation therapy (ADT) is most common non-operative treatments for localised prostate cancer (PC). Some circulatory cytokines are believed to play an important role in RT resistance and lead to tumour progression, invasion, and angiogenesis. The aim of this study is to assess the influence of ADT and RT on the expression of circulatory cytokines levels in plasma at different time points. METHODS: Between Nov 2015 and Aug 2016, 18 patients with localized PC were selected for this clinical study. All patients had received neoadjuvant ADT using a leuteinizing hormone-releasing hormone (LH-RH) analogs prior to RT. Peripheral blood samples were collected prior to ADT, before RT, at the end of RT and 3 months after the completion of RT. Blood plasma samples were monitored for the pro-inflammatory and profibrotic cytokines TNF-α, TGF-β1, IL-6, and IL-8, using enzyme-linked immunosorbent assay (ELISA) procedures. RESULTS: The concentration of TGF-β1 rose while IL-6 levels declined in post-ADT samples when compared pre-ADT. Levels of TGF-β1 increased in post-RT blood plasma compared to pre-RT blood plasma. Those changes were not statically significant. Three months post-RT completion, TGF-β1 levels decreased and IL-6 and IL-8 levels increased. Although levels of TGF-β1, IL-6 and IL-8 were found to be altered 3 months post-RT completion, only changes in IL-8 levels were found to be statistically significant (P=0.05). CONCLUSIONS: In conclusion the changes in cytokines levels have been found after ADT and RT, which strengthen the finding of other clinical studies. Accept that small numbers of samples made difficult to attain significant results. Large clinical studies will be required to validate these findings and hopefully become useful biomarkers in the clinical setting to predict patient outcome and success of treatment received. AME Publishing Company 2020-05 /pmc/articles/PMC7290633/ /pubmed/32566573 http://dx.doi.org/10.21037/atm-19-1913 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Singh, Jagtar
Sohal, Sukhwinder Singh
Ahuja, Kiran
Lim, Aijye
Duncan, Henry
Thachil, Thanuja
De Ieso, Paolo
Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
title Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
title_full Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
title_fullStr Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
title_full_unstemmed Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
title_short Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
title_sort levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290633/
https://www.ncbi.nlm.nih.gov/pubmed/32566573
http://dx.doi.org/10.21037/atm-19-1913
work_keys_str_mv AT singhjagtar levelsofplasmacytokineinpatientsundergoingneoadjuvantandrogendeprivationtherapyandexternalbeamradiationtherapyforadenocarcinomaoftheprostate
AT sohalsukhwindersingh levelsofplasmacytokineinpatientsundergoingneoadjuvantandrogendeprivationtherapyandexternalbeamradiationtherapyforadenocarcinomaoftheprostate
AT ahujakiran levelsofplasmacytokineinpatientsundergoingneoadjuvantandrogendeprivationtherapyandexternalbeamradiationtherapyforadenocarcinomaoftheprostate
AT limaijye levelsofplasmacytokineinpatientsundergoingneoadjuvantandrogendeprivationtherapyandexternalbeamradiationtherapyforadenocarcinomaoftheprostate
AT duncanhenry levelsofplasmacytokineinpatientsundergoingneoadjuvantandrogendeprivationtherapyandexternalbeamradiationtherapyforadenocarcinomaoftheprostate
AT thachilthanuja levelsofplasmacytokineinpatientsundergoingneoadjuvantandrogendeprivationtherapyandexternalbeamradiationtherapyforadenocarcinomaoftheprostate
AT deiesopaolo levelsofplasmacytokineinpatientsundergoingneoadjuvantandrogendeprivationtherapyandexternalbeamradiationtherapyforadenocarcinomaoftheprostate